Ecovia Bio, an advanced biotechnology company in Livonia specializing in sustainable, high-performance biopolymer ingredients for skincare products, has closed a Series B funding round led by Pointe Angels, an independent angel investor group based in the Grosse Pointe communities.
The funding will support “significant” expansion of Ecovia Bio’s manufacturing capacity.
The Series B round is expected to fuel a comprehensive expansion program that increases production capacity across Ecovia Bio’s Livonia manufacturing facility. With this investment, the company projects the facility will achieve full operational capacity by 2028, positioning Ecovia Bio to serve growing customer demand across multiple high-growth markets.
The company has begun evaluation of additional production facilities to accommodate market demand beyond 2028 and secure long-term supply chain security for global partners.
“We are excited to partner with Pointe Angels,” says Kousay Said, CEO of Ecovia Bio. “This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale.”
Ecovia Bio’s products are designed to reduce dependence on petrochemicals while delivering “superior” performance in “demanding” applications, according to the company. By expanding manufacturing capacity and establishing the roadmap for additional production sites, Ecovia Bio says it’s positioning itself to become the trusted global supplier of choice for γ-PGA and related biopolymers across consumer and industrial markets.
Superabsorbent polymers (SAPs) — synthetic, petrochemical-derived plastics used extensively in diapers, feminine hygiene products, cosmetics, lotions, and other consumer goods — persist in landfills for centuries and fragment into harmful microplastics that contaminate soil, water systems, and the food chain. These microplastics have been detected in human blood, lungs, and placental tissue, raising serious health concerns.
Ecovia Bio says its biodegradable γ-PGA technology represents a “transformative solution,” enabling manufacturers to replace synthetic polymers with a bio-based, fully biodegradable alternative that delivers equivalent or superior performance without environmental or health consequences.
By scaling production of γ-PGA, Ecovia Bio is advancing a global shift toward truly sustainable consumer products, addressing regulatory pressures, meeting consumer demand for safer products, and addressing the urgent need to protect human health and environmental integrity.
“Ecovia Bio represents exactly the kind of venture we love to back at Pointe Angels,” says David Bloom, executive director of Pointe Angels. “The company has solved a real technical challenge — producing sustainable, high-performance γ-PGA at commercial scale — and now has the market traction to justify expansion.
“What impressed us most was the management team’s disciplined approach to capacity planning and their ability to serve multiple end markets from a single, optimized manufacturing platform. We’re confident this capital will unlock significant value for our investors while strengthening Michigan’s position as a leader in biotechnology and advanced manufacturing.”
